Crux Biolabs
Bayswater, Australia· Est.
Australian‑based CRO delivering accredited immunology and biomarker services for global biotech and pharma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian‑based CRO delivering accredited immunology and biomarker services for global biotech and pharma.
ImmunologyOncologyInflammation
Technology Platform
Core capabilities include ISO‑17025 accredited flow cytometry (13‑colour CytoFlex), Luminex multiplex cytokine panels, FluoroSpot T‑cell functional assays, ELISA, PBMC processing, and analytical chemistry for PK, all validated to FDA/EMA guidelines.
Opportunities
Growing demand for high‑throughput immunomonitoring and multiplex biomarker analysis, combined with Australia’s R&D tax incentives, positions Crux to attract more international biotech sponsors and expand its service portfolio.
Risk Factors
Reliance on regulatory compliance and accreditation; competition from larger global CROs; scaling laboratory capacity without compromising quality.
Competitive Landscape
Competes with CROs such as Charles River, Labcorp and Eurofins, differentiating through ISO‑17025 accreditation, GCLP‑validated immunology assays, and cost advantages of the Australian ecosystem.